GlobeNewswire Inc.Oct 26, 6:00 AM ET▲ Positive
The SPAC is successfully completing a business combination with a clinical-stage biotech company backed by substantial PIPE financing ($300M) from reputable healthcare investors. The deal provides clear strategic value with a late-stage obesity drug candidate (CX11) that has demonstrated positive Phase 2 results and FDA alignment on regulatory pathway, positioning the combined company for growth through 2029.